Prognostic and clinicopathological significance of systemic immune-inflammation index in pancreatic cancer: a meta-analysis of 2,365 patients

Yifang Shui¹,²,³,⁴,⁵, Mengquan Li⁵, Jing Su⁵, Mingxun Chen⁶, Xiaobin Gu⁷, Wenzhi Guo¹,²,³,⁴

¹Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China
²Henan Key Laboratory of Digestive Organ Transplantation, Zhengzhou 450052, Henan, China
³Open and Key Laboratory of Hepatobiliary and Pancreatic Surgery and Digestive Organ Transplantation at Henan Universities, Zhengzhou 450052, Henan, China
⁴Zhengzhou Key Laboratory of Hepatobiliary and Pancreatic Diseases and Organ Transplantation, Zhengzhou 450052, Henan, China
⁵Department of Breast Disease Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China
⁶Department of Hepatobiliary and Pancreatic Surgery, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou 450007, Henan, China
⁷Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China

Correspondence to: Xiaobin Gu, Wenzhi Guo; email: fahzugu@126.com, https://orcid.org/0000-0002-4785-1924; guowz66@163.com

Keywords: meta-analysis, pancreatic cancer, prognosis, biomarker, systemic immune-inflammation index

Received: December 15, 2020 Accepted: August 2, 2021 Published: August 25, 2021

Copyright: © 2021 Shui et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

The prognostic value of the systemic immune-inflammation index (SII) in patients with pancreatic cancer is conflicting according to previous investigations. Therefore, we performed a meta-analysis to explore the association between SII and pancreatic cancer prognosis. Electronic databases were searched for studies exploring the association of SII with prognostic outcomes in pancreatic cancer. The endpoints were overall survival (OS), disease-free survival (DFS), recurrence-free survival (RFS), progression-free survival (PFS), cancer-specific survival (CSS), and clinicopathological parameters. The prognostic value of SII was estimated by hazard ratio (HR) or odds ratio (OR) with a 95% confidence interval (CI). Nine studies containing 11 cohorts with 2,365 subjects in total were included in this meta-analysis. Elevated SII was associated with poor OS (HR=1.50, 95% CI=1.15–1.96, p=0.002), RFS/PFS/DFS (HR=1.52, 95% CI=1.01–2.28, p=0.045), and CSS (HR=2.60, 95% CI=1.65–4.09, p < 0.001) in patients with pancreatic cancer. Additionally, there was no significant association between SII and other parameters in pancreatic cancer such as sex, tumor location, lymph node metastasis, tumor-node-metastasis stage, vascular invasion, and grade. This meta-analysis suggested that elevated SII was a significant prognostic marker for short-term and long-term survival outcomes in patients with pancreatic cancer.

INTRODUCTION

Pancreatic cancer is a highly aggressive malignant tumor and the seventh leading cause of cancer-related deaths worldwide [1, 2]. In 2018, 458,918 new cases and 432,242 deaths due to pancreatic cancer occurred globally [1]. A lack of reliable early biomarkers causes 85% of patients to be diagnosed with metastatic or
locally advanced disease [3]. The prognosis of pancreatic cancer is poor with a 5-year survival rate of less than 5% [4]. Surgical resection is the only curative approach for pancreatic cancer and is feasible in 15% of the cases [4]. However, even for patients with operable pancreatic cancer, the 5-year survival rate is only 18%–24% [5]. One of the major reasons for the poor prognosis is the lack of effective biomarkers [4]; therefore, identification of novel prognostic markers is pivotal for better management of patients with pancreatic cancer.

Various studies have shown that systemic inflammation plays an important role in cancer progression [6]. Systemic inflammatory responses are involved in the initiation, promotion, and metastasis of cancer cells [7]. In the recent years, the systemic immune-inflammation index (SII), which is calculated as platelet count × neutrophils/lymphocytes, has been reported as a noninvasive prognostic marker for various solid tumors [8, 9]. The prognostic value of SII in patients with pancreatic cancer has also been explored by many researchers [10–15]; however, the results are conflicting. For example, elevated SII in patients with pancreatic cancer was found to be associated with poor survival outcomes in some studies [14, 15] and favorable prognosis in other studies [11]. Therefore, in this study, we collected the literature published in this area of study and conducted a meta-analysis. We hypothesized that elevated SII could be a significant prognostic factor for patients with pancreatic cancer. We aimed to clarify the prognostic impact of SII on pancreatic cancer and analyze the correlation between SII and the clinicopathological features of pancreatic cancer.

RESULTS

Literature search and study characteristics

The initial literature search identified 64 studies, out of which, 23 studies were selected after eliminating the duplicate records. Following the examination of titles and abstracts, 11 studies were excluded, and the entire text of the remaining 12 studies was examined. Subsequently, six studies were excluded for the following reasons: two studies did not provide survival outcomes, two studies did not identify the cut-off value of SII, one study did not provide usable data for analysis, and one study was a meeting abstract. Following an updated literature search, three additional studies [16–18] were included in the meta-analysis.

At the end of the selection process, nine studies [10–18] were included in this meta-analysis (Figure 1). In the studies by Aziz et al. [10] and Zhang et al. [14] studies, two independent cohorts were recruited in each study, which were labeled as cohorts Aziz, M. H. (B) [10], Aziz, M. H. (B) [10], Zhang, K. (A) [14], and Zhang, K. (B) [14]. Therefore, nine studies containing 11 cohorts were included in the meta-analysis. The basic characteristics of the included studies are listed in Supplementary Table 1; these studies were published from 2019 to 2021. The 11 cohort studies were conducted in China (n=4) [12, 14, 15, 17, 18], the Netherlands (n=2) [10], Austria (n=1) [11], Italy (n=1) [16], and the United States of America (USA) (n=1) [13]. The sample size ranged from 27 to 420, and the total sample size was 2,365. Nine cohort studies [10–14, 16, 17] were published in English and two [15, 18] were published in Chinese. Regarding the study design, nine cohorts [10, 12–18] were retrospective studies and two [11, 12] were prospective studies. The cut-off value of SII ranged from 440 to 1200. Nine cohorts [11–18] reported the prognostic role of SII in OS, six cohorts [10–12, 16, 17] reported an association between SII and RFS/PFS/DFS, and two cohorts reported CSS [10]. The Newcastle-Ottawa Scale (NOS) scores ranged from 6 to 8, indicating that all the studies included were of high quality.

SII and OS in pancreatic cancer

A total of nine cohorts with 1,775 subjects [11–18] reported an association between SII and OS in pancreatic cancer. A random-effects model (REM) was used because of significant heterogeneity ($I^2 = 76.4\%$, $P < 0.001$). The pooled results were as follows: $HR=1.50$, 95% CI =1.15–1.96, $p=0.002$ (Figure 2; Table 1), suggesting that SII was not a significant prognostic marker for OS. In the subgroup analysis of these patients with pancreatic cancer, the results demonstrated that SII was a significant prognostic factor for OS in patients of Asian ethnicity, in stage III-IV/recurrent disease, in retrospective studies, and with an SII cut-off value $\geq 900$ (Table 1).

SII and RFS/PFS/DFS in pancreatic cancer

Six cohorts, with 1,297 subjects [10–12, 16, 17], reported the prognostic value of SII for RFS/PFS/DFS. As shown in Figure 3 and Table 1, the pooled results were as follows: $HR=1.52$, 95% CI =1.01–2.28, $p=0.045$. The combined data indicated that SII was significantly associated with RFS/PFS/DFS in pancreatic cancer. Similar to the results of OS, the subgroup analysis of these patients with pancreatic cancer showed that a high SII was an indicator of poor RFS/PFS/DFS in patients of Asian ethnicity, in stage III-IV/recurrent disease, in retrospective studies, and with an SII cut-off value $\geq 900$ (Table 1).
SII and CSS in pancreatic cancer

The association between SII and CSS was analyzed based on the data from two cohorts [10]. The pooled results were as follows: HR=2.60, 95% CI=1.65–4.09, p < 0.001 (Figure 4; Table 1), which indicated that elevated SII had significant correlation with a low CSS in pancreatic cancer. Subgroup analysis was not performed as only two cohorts were included in the analysis.

The association between SII and clinicopathological characteristics

The association between SII and clinicopathological factors was investigated based on the data from six cohorts [11, 13–15, 18]. As shown in Figure 5 and Table 2, there was no significant association between SII and sex (male vs. female) (OR=1.09, 95% CI=0.87–1.36, p=0.469), tumor location (head vs. body/tail) (OR=1.33, 95% CI=0.97–1.81, p=0.074), lymph node metastasis (yes vs. no) (OR=1.27, 95% CI=0.96–1.69, p=0.093), tumor-node-metastasis stage (III-IV vs. I-III) (OR=1.02, 95% CI=0.63–1.66, p=0.798), vascular invasion (yes vs. no) (OR=1.33, 95% CI=0.89–1.97, p=0.160), or grade (3–4 vs 1–2) (OR=1.07, 95% CI=0.77–1.50, p=0.671).

Publication bias

Publication bias was analyzed using Begg’s funnel plots and Egger’s regression test. As shown in Figure 6,
the results indicated that there was no significant publication bias in this meta-analysis.

**DISCUSSION**

The previous studies published contradictory reports on the prognostic value of SII in patients with pancreatic cancer [10–15]. In this meta-analysis of data gathered from 11 cohorts, with 2,365 subjects, we demonstrated that elevated SII was a significant prognostic factor for OS, RFS/PFS/DFS, and CSS in pancreatic cancer. The subgroup analysis indicated that elevated SII was predictive of low OS and RFS/PFS/DFS in patients of Asian ethnicity, in stage III-IV/recurrent disease, and with a SII cut-off value ≥ 900. In addition, we found that there was no significant correlation between SII and several clinicopathological features in patients with pancreatic cancer. The null association between SII and clinicopathological characteristics could have resulted because of the limited sample size in each group. In conclusion, this meta-analysis demonstrated that elevated SII was associated with poor short-term and long-term survival outcomes. Elevated SII correlated with poor long-term survival outcomes in patients of Asian ethnicity. We opine that SII is an easily available and effective biomarker which can be utilized for the prognostication of patients with pancreatic cancer in clinical practice. To the best of our knowledge, this study is the first meta-analysis to explore the prognostic value of SII in pancreatic cancer.

In the recent years, there has been accumulating evidence on the relationship between cancer progression and inflammatory response [19, 20]. A series of inflammatory biomarkers, including neutrophil/lymphocyte ratio [21, 22], platelet to lymphocyte ratio [23, 24], and SII have been proven effective for prognosis prediction in patients with cancer. SII is defined as platelet count × neutrophil count/lymphocyte count, which considers the combined effect of platelet, neutrophil, and lymphocyte counts. Elevated SII represents an increase in platelet and neutrophil counts and/or a decrease in lymphocyte count. Platelets can directly promote the growth of tumor

![Image](Figure 2. Forest plot reflecting the association between SII and OS in pancreatic cancer. A random-effects model (REM) was used because of significant heterogeneity ($I^2 = 76.4\%, P < 0.001$). The pooled HR and 95%CI are: HR=1.50, 95%CI=1.15-1.96, p=0.002. SII= systemic immune-inflammation index, OS=overall survival.)
Table 1. Subgroup analysis of the prognostic role of SII for OS, RFS/PFS/DFS, and CSS for patients with pancreatic cancer.

| Subgroups          | Studies (n) | Patients (n) | HR (95% CI)       | p     | Effects model | Heterogeneity |
|--------------------|-------------|--------------|-------------------|-------|---------------|---------------|
|                    |             |              |                   |       |               | P (%)         | Ph            |
| OS                 |             |              |                   |       |               |               |
| Total              | 9           | 1,775        | 1.50 (1.15-1.96)  | 0.002 | REM           | 76.4          | <0.001        |
| Ethnicity          |             |              |                   |       |               |               |
| Caucasian          | 3           | 977          | 1.24 (0.69-2.24)  | 0.477 | REM           | 89.1          | <0.001        |
| Asian              | 6           | 798          | 1.55 (1.33-1.80)  | <0.001| REM           | 25.6          | 0.243         |
| Sample size <200  | 5           | 576          | 1.59 (1.33-1.91)  | <0.001| REM           | 37.8          | 0.169         |
| ≥200               | 4           | 1,199        | 1.28 (0.84-1.97)  | 0.251 | REM           | 86.0          | <0.001        |
| TNM stage          |             |              |                   |       |               |               |
| I-II               | 4           | 973          | 1.22 (0.83-1.81)  | 0.311 | REM           | 83.5          | <0.001        |
| III-IV/recurrent   | 5           | 802          | 1.63 (1.36-1.95)  | <0.001| FEM           | 47.4          | 0.107         |
| SII cut-off value  |             |              |                   |       |               |               |
| <900               | 6           | 987          | 1.47 (1.00-2.14)  | 0.048 | REM           | 82.6          | <0.001        |
| ≥900               | 3           | 788          | 1.57 (1.26-1.95)  | <0.001| FEM           | 12.8          | 0.318         |
| Study design       |             |              |                   |       |               |               |
| Retrospective      | 7           | 1,424        | 1.52 (1.34-1.74)  | <0.001| FEM           | 14.6          | 0.319         |
| Prospective        | 2           | 351          | 1.32 (0.36-4.89)  | 0.680 | REM           | 89.1          | 0.002         |
| Cut-off determination |         |              |                   |       |               |               |
| ROC analysis       | 5           | 802          | 1.74 (0.96-3.14)  | 0.068 | REM           | 86.6          | <0.001        |
| X-tile/other       | 4           | 973          | 1.47 (1.26-1.72)  | <0.001| FEM           | 0             | 0.895         |
| RFS/PFS/DFS        |             |              |                   |       |               |               |
| Total              | 6           | 1,297        | 1.52 (1.01-2.28)  | 0.045 | REM           | 72.5          | 0.003         |
| Ethnicity          |             |              |                   |       |               |               |
| Caucasian          | 4           | 1,148        | 1.27 (0.83-1.93)  | 0.267 | REM           | 73.9          | 0.009         |
| Asian              | 2           | 149          | 2.76 (1.45-5.25)  | 0.002 | FEM           | 0             | 0.944         |
| Sample size <200  | 3           | 170          | 1.96 (1.26-3.05)  | 0.003 | FEM           | 2.1           | 0.360         |
| ≥200               | 3           | 978          | 1.23 (0.73-2.07)  | 0.429 | REM           | 81.5          | 0.005         |
| TNM stage          |             |              |                   |       |               |               |
| I-II               | 3           | 914          | 1.19 (0.69-2.04)  | 0.527 | REM           | 72.8          | 0.025         |
| III-IV/recurrent   | 3           | 234          | 1.73 (1.28-2.35)  | <0.001| FEM           | 22.6          | 0.275         |
| SII cut-off value  |             |              |                   |       |               |               |
| <900               | 3           | 473          | 1.68 (0.62-4.55)  | 0.303 | REM           | 83.5          | 0.002         |
| ≥900               | 3           | 824          | 1.55 (1.19-2.02)  | 0.001 | FEM           | 0             | 0.908         |
| Study design       |             |              |                   |       |               |               |
| Retrospective      | 4           | 946          | 1.61 (1.24-2.08)  | <0.001| FEM           | 0             | 0.685         |
| Prospective        | 2           | 351          | 1.37 (0.41-4.57)  | 0.609 | REM           | 86.7          | 0.006         |
| CSS                |             |              |                   |       |               |               |
| Total              | 2           | 590          | 2.60 (1.65-4.09)  | <0.001| FEM           | 0             | 0.721         |

HR, hazards ratio; CI, confidence interval; ROC, receiver operating characteristic; OS, overall survival; RFS, recurrence-free survival; DFS, disease-free survival; PFS, progression-free survival; CSS, cancer-specific survival; TNM, Tumor-Node-Metastasis; REM, random-effects model; FEM, fixed-effects model.

cells by secreting various cytokines that facilitate angiogenesis and tumor progression [25]. In addition, tumor-infiltrating neutrophils have been shown to play an important role in tumor progression [26]. In contrast, lymphocytes play a major role in suppressing cancer cell proliferation and migration [27]. Tumor-infiltrating lymphocytes (TILs) can exert anti-tumor activity by inducing cytotoxic cell death and cytokine production [28]. Therefore, elevated SII being an indicator of poor prognosis is based on the diverse roles of platelets, neutrophils, and TILs in tumor biology.

Recently, many meta-analyses have explored the prognostic effect of SII in various solid tumors [29–33]. In a study on patients with breast cancer, Zhang et al. showed that an elevated SII predicted poor survival
Figure 3. Forest plot reflecting the association between SII and RFS/PFS/DFS in pancreatic cancer. (HR=1.52, 95%CI=1.01-2.28, p=0.045). SII= systemic immune-inflammation index, RFS=recurrence-free survival, DFS= disease-free survival, PFS = progression-free survival.

Figure 4. Forest plot reflecting the association between SII and CSS in pancreatic cancer. The combined results were: HR=2.60, 95%CI=1.65-4.09, p<0.001, which indicated that elevated SII was significantly correlated to inferior CSS in pancreatic cancer. SII= systemic immune-inflammation index, CSS= cancer-specific survival.
outcomes and was associated with clinicopathological features that indicated tumor progression [33]. In another recent meta-analysis, which included 3,074 patients, the researchers indicated that SII might be a promising noninvasive predictor in patients with urologic cancers [30]. Wang’s meta-analysis of 2,796 patients demonstrated that elevated SII was a poor prognostic factor for patients with hepatocellular carcinoma [32]. Our previous meta-analysis showed that elevated SII levels predicted poor prognosis in patients with colorectal cancer. In addition, elevated SII levels were also associated with clinical factors, implying higher malignancy of the disease [29]. In compliance with the results of the previous meta-analysis, the present meta-analysis showed that an elevated SII was associated with poor CSS in pancreatic cancer. Furthermore, the results also indicated that the SII is an effective marker for OS and DFS in Asian

Figure 5. Forest plots showing the association between SII and clinicopathological factors in pancreatic cancer. (A) sex (male vs female); (B) tumor location (head vs body/tail); (C) lymph node metastasis; (D) Tumor-Node-Metastasis (TNM) stage (III-IV vs I-III); (E) grade (3-4 vs 1-2), and (F) vascular invasion (yes vs no).
Table 2. Correlation between SII and clinicopathological features in patients with pancreatic cancer.

| Factors                              | Studies (n) | Patients (n) | OR (95% CI)   | p     | Effects model | Heterogeneity I² (%) | Ph   |
|--------------------------------------|-------------|--------------|----------------|-------|---------------|----------------------|------|
| Sex (male vs female)                 | 6           | 1,392        | 1.09(0.87-1.36) | 0.469 | FEM           | 0                    | 0.874|
| Tumor location (Head vs body/tail)   | 4           | 878          | 1.33(0.97-1.81) | 0.074 | FEM           | 15.6                 | 0.314|
| Lymph node metastasis (Yes vs no)    | 4           | 973          | 1.27(0.96-1.69) | 0.093 | FEM           | 45.6                 | 0.138|
| TNM stage (III-IV vs I-III)          | 4           | 973          | 1.02(0.63-1.66) | 0.798 | REM           | 56.0                 | 0.103|
| Grade (3-4 vs 1-2)                   | 3           | 878          | 1.07(0.77-1.50) | 0.671 | FEM           | 0                    | 0.394|
| Vascular invasion (Yes vs no)        | 2           | 514          | 1.33(0.89-1.97) | 0.160 | FEM           | 0                    | 0.610|

OR, odds ratio; CI, confidence interval; TNM, Tumor-Node-Metastasis; REM, random-effects model; FEM, fixed-effects model.

Figure 6. Begg’s funnel plot and Egger’s linear regression test for publication bias in this meta-analysis. (A) Begg’s funnel plot for OS (p=0.089); (B) Egger’s linear regression test for OS (p=0.057); (C) Begg’s funnel plot for RFS/PFS/DFS (p=0.260); (D) Egger’s linear regression test for RFS/PFS/DFS (p=0.160); (E) Begg’s funnel plot for CSS (p=1), and (F) Egger’s linear regression test for CSS (p=1).
patients, which suggests that SII may be more applicable in patients of Asian ethnicity. However, the data indicated a non-significant association between SII and the clinicopathological factors of pancreatic cancer. This may be due to the relatively small sample size. Notably, the meta-analysis did not include unpublished studies and conference abstracts for the following reasons: Firstly, the unpublished literature and conference abstracts did not present full text including the results and the process of data analysis. Secondly, the full-text articles published in peer-reviewed journals were preferred because of their high quality and reliable results. Thirdly, publication bias tests did not detect publication bias or selection bias in this meta-analysis.

Nevertheless, our study has several limitations. Firstly, the sample size was relatively small. Although 11 cohorts were included, the total sample size was 2,365. The relatively small sample size might have resulted in a null association between SII and clinicopathological factors of pancreatic cancer. Secondly, this meta-analysis was limited to studies published in English and Chinese as the publications in other languages were unavailable. This could have led to a possible selection bias in this meta-analysis. Thirdly, the cut-off values of SII vary among the studies included, which may significantly contribute to substantial heterogeneity in this meta-analysis. Therefore, a uniform cut-off value for SII is needed in further studies.

In summary, this meta-analysis suggests that an elevated SII is a significant prognostic marker for short-term and long-term survival outcomes. The SII has a significant prognostic role in Asian patients with pancreatic cancer. Therefore, we suggest that SII be employed as an effective biomarker for the prognosis of patients with pancreatic cancer in clinical practice.

**MATERIALS AND METHODS**

**Literature search strategy**

This meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement [34]. The electronic databases PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure, and China Wanfang databases were searched systematically. The search strategy was as follows: (“systemic immune-inflammation index” or “SII”) and (“pancreatic cancer” or “pancreatic neoplasms” or “pancreatic adenocarcinoma” or “pancreatic tumor”). The search duration was from inception to March 25, 2021. There were no language restrictions. In addition, the references of the included publications and reviews were manually checked for potentially eligible studies.

**Inclusion and exclusion criteria**

Two investigators (Y.S. and M.L.) independently performed the literature search, and any disagreements were resolved by consensus. The selection criteria were established based on previous meta-analyses of the SII [29, 32, 33]. The inclusion criteria were as follows: (a) diagnosis of pancreatic cancer was pathologically confirmed; (b) SII was defined as the neutrophil count × platelet count/lymphocyte count; (c) patients who did not have active infections, inflammatory conditions, or comorbid diseases before blood examination; (d) studies exploring the association between SII and survival outcomes in pancreatic cancer with hazard ratios (HRs) and 95% confidence intervals (CIs); (e) the cut-off value of SII was provided; and (f) articles published in English or Chinese. The exclusion criteria were as follows: (a) meeting abstracts, reviews, letters, case reports, and comments; (b) animal studies; and (c) insufficient information available for data analysis. Outcomes of interest included overall survival (OS), recurrence-free survival (RFS), progression-free survival (PFS), disease-free survival (DFS), and cancer-specific survival (CSS). The primary endpoint was the OS, and the secondary endpoints were the RFS/PFS/DFS and CSS.

**Data extraction and quality assessment**

Two investigators (Y.S. and M.C.) independently extracted data from the included studies, and discrepancies were resolved by discussion with a third investigator (X.G.). The following information was extracted: name of the first author, year of publication, country, sample size, age, histological type, tumor stage, treatment, study period, cut-off value of SII, cut-off determination method, study design, follow-up, survival endpoints, survival analysis, and the HRs and 95% CIs of survival outcomes. The quality of the included studies was evaluated using the NOS [35], which evaluates the quality of the study in three aspects: selection, comparability, and exposure. The NOS scores range from 0 to 9. Studies with NOS score of 6 or more were regarded as high-quality studies.

**Statistical analysis**

The HRs and 95% CIs were used to evaluate the prognostic role of the SII for OS, RFS/PFS/DFS, and CSS in pancreatic cancer. The heterogeneity among studies was assessed using the Cochran’s Q test and I² statistics. In the presence of significant heterogeneity (I² > 50% and/or P < 0.10), REM was used to combine the HRs and 95% CIs. Otherwise, a fixed-effects model (FEM) was adopted. Subgroup analysis was conducted to explore the sources of heterogeneity. The association
between SII and clinicopathological factors was evaluated using odds ratios and 95% CIs. Publication bias was estimated using the Begg’s test and Egger’s test. Statistical significance was set at p < 0.05. All the statistical analyses were performed using Stata version 12.0 (Stata Corporation, College Station, TX, USA).

AUTHOR CONTRIBUTIONS

Y.S. and M.L. conceived the study and designed the protocol. Y.S., J.S., M.C., and X.G. performed the literature search. Y.S., X.G., and W.G. selected the studies and extracted the relevant information. M.L., J.S., M.C., and X.G. synthesized the data. X.G. wrote the first draft of the paper. All authors critically revised successive drafts of the paper and approved the final version. X.G. is the guarantor.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

FUNDING

This study was supported by the Key Scientific Research Project of Colleges and Universities in Henan Province (grant No. 21A320043) and the Joint Construction Project of Medical Science and Technology Research Program of Henan Province (grant No. LHJG20190019). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394–424. https://doi.org/10.3322/caac.21492 PMID:30207593

2. Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, Abdel-Rahman O, Abdelalim A, Abdoli A, Abdollahpour I, Abulkes AS, Abebe ND, Abraha HN, Abu-Raddad LJ, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2019; 5:1749–68. https://doi.org/10.1001/jamaoncol.2019.2996 PMID:31560378

3. Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018; 15:333–48. https://doi.org/10.1038/s41575-018-0005-x PMID:29717230

4. Buscail E, Maulat C, Muscari F, Chiche L, Cordelier P, Dabernat S, Alik-Panabieres C, Buscail L. Liquid Biopsy Approach for Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2019; 11:852. https://doi.org/10.3390/cancers11060852 PMID:31248203

5. Qi ZJ, Yu D, Chen CH, Jiang H, Li R, Kang YM. The prognostic value of B7H1 and B7H4 expression in pancreatic cancer: A meta-analysis. Int J Biol Markers. 2019; 34:373–80. https://doi.org/10.1177/1724600819881147 PMID:31608800

6. Hou T, Guo T, Nlie R, Hong D, Zhou Z, Zhang X, Liang Y. The prognostic role of the preoperative systemic immune-inflammation index and high-sensitivity modified Glasgow prognostic score in patients after radical operation for soft tissue sarcoma. Eur J Surg Oncol. 2020; 46:1496–502. https://doi.org/10.1016/j.ejso.2020.05.026 PMID:32576479

7. Dai J, Lu Y, Roca H, Keller JM, Zhang J, McCauley LK, Keller ET. Immune mediators in the tumor microenvironment of prostate cancer. Chin J Cancer. 2017; 36:29. https://doi.org/10.1186/s40880-017-0198-3 PMID:28292326

8. Xie H, Yuan G, Huang S, Kuang J, Yan L, Ruan G, Tang S, Gan J. The prognostic value of combined tumor markers and systemic immune-inflammation index in colorectal cancer patients. Langenbecks Arch Surg. 2020; 405:1119–30. https://doi.org/10.1007/s00423-020-01963-3 PMID:32794068

9. Ozbek E, Besiroglu H, Ozer K, Horsanali MO, Gorgel SN. Systemic immune inflammation index is a promising non-invasive marker for the prognosis of the patients with localized renal cell carcinoma. Int Urol Nephrol. 2020; 52:1455–63. https://doi.org/10.1007/s11255-020-02440-y PMID:32172455

10. Aziz MH, Siders K, Aziz NA, Mauff K, Haen R, Roos D, Saida L, Suker M, van der Harst E, Mieg JS, Bonsing BA, Klaver Y, Koerkamp S, van Eijck CH. The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels: A Retrospective Multicenter Cohort Study. Ann Surg. 2019; 270:139–46.
11. Jomrich G, Gruber ES, Winkler D, Hollenstein M, Gnant M, Sahora K, Schindl M. Systemic Immune-Inflammation Index (SII) Predicts Poor Survival in Pancreatic Cancer Patients Undergoing Resection. J Gastrointest Surg. 2020; 24:610–18. https://doi.org/10.1007/s11605-019-04187-z PMID: 30923999

12. Li J, Wang Z, Li AM, Zhou H, Zhu X. Analysis of the efficacy, safety and survival factors of stereotactic body radiation therapy in patients with recurrence of pancreatic cancer. Transl Oncol. 2020; 13:100818. https://doi.org/10.1016/j.tranon.2020.100818 PMID: 32592902

13. Murthy P, Zenati MS, Al Abbas AI, Rieser CJ, Bahary N, Lotze MT, Zeh HJ 3rd, Zureikat AH, Boone BA. Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer. Ann Surg Oncol. 2020; 27:898–906. https://doi.org/10.1245/s10434-019-08094-0 PMID: 31792715

14. Zhang K, Hua YQ, Wang D, Chen LY, Wu CJ, Chen Z, Liu LM, Chen H. Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer. J Transl Med. 2019; 17:30. https://doi.org/10.1186/s12967-019-1782-x PMID: 30658662

15. Zhao Y, Cheng J. Relationship between the systemic immune-inflammation index and the prognosis of pancreatic ductal adenocarcinoma patients after neoadjuvant chemotherapy. Chin J of Oncol Prev and Treat. 2020; 12:222–27. https://doi.org/10.3969/j.issn.1674-5671.2020.02.21

16. Bittoni A, Pecci F, Mentrasti G, Crocetti S, Lupi A, Lanese A, Pellei C, Ciotti C, Cantini L, Giampieri R, Lenci E, Giglio E, Bini F, et al. Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer. Ann Transl Med. 2021; 9:251. https://doi.org/10.21037/atm-20-3499 PMID: 33708878

17. Shang J, Han X, Zha H, Tao H, Li X, Yuan F, Chen G, Wang L, Ma J, Hu Y. Systemic Immune-Inflammation Index and Changes of Neutrophil-Lymphocyte Ratio as Prognostic Biomarkers for Patients With Pancreatic Cancer Treated With Immune Checkpoint Blockade. Front Oncol. 2021; 11:585271. https://doi.org/10.3389/fonc.2021.585271 PMID: 33718140

18. Xu C, Pan J, Wu T, Mo Z, Zhu T, Feng L. Predictive value of the systemic immune inflammatory index on the overall survival rate of patients after Whipple surgery for pancreatic ductal adenocarcinoma. Chin J Hepatobiliary Surg. 2021; 27:206–10.

19. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140:883–99. https://doi.org/10.1016/j.cell.2010.01.025 PMID: 20303878

20. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646–74. https://doi.org/10.1016/j.cell.2011.02.013 PMID: 21376230

21. Zhou Y, Wei Q, Fan J, Cheng S, Ding W, Hua Z. Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: A meta-analysis containing 8252 patients. Clin Chim Acta. 2018; 479:181–89. https://doi.org/10.1016/j.cca.2018.01.024 PMID: 29407690

22. Zhang X, Jiang Y, Wang Y, Wang Z, Zhao L, Xue X, Sang S, Zhang L. Prognostic role of neutrophil-lymphocyte ratio in esophageal cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2018; 97:e13585. https://doi.org/10.1097/MD.0000000000013585 PMID: 30544482

23. Zhang Y, Zheng L, Quan L, Du L. Prognostic role of platelet-to-lymphocyte ratio in oral cancer: A meta-analysis. J Oral Pathol Med. 2021; 50:274–79. https://doi.org/10.1111/jop.12832 PMID: 30681182

24. Yang L, Huang Y, Zhou L, Dai Y, Hu G. High pretreatment neutrophil-to-lymphocyte ratio as a predictor of poor survival prognosis in head and neck squamous cell carcinoma: Systematic review and meta-analysis. Head Neck. 2019; 41:1525–35. https://doi.org/10.1002/hed.25583 PMID: 30597654

25. Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost. 2011; 9: 237–49. https://doi.org/10.1111/j.1538-7836.2010.04131.x PMID: 21040448

26. Mu S, Ai L, Fan F, Sun C, Hu Y. Prognostic role of neutrophil-lymphocyte ratio in multiple myeloma: a dose-response meta-analysis. Onco Targets Ther. 2018; 11:499–507. https://doi.org/10.2147/OTT.S153146 PMID: 29416350

27. Bastid J, Bonnefoy N, Eliaou JF, Bensussan A. Lymphocyte-derived interleukin-17A adds another brick in the wall of inflammation-induced breast carcinogenesis. Oncoimmunology. 2014; 3:e28273. https://doi.org/10.4161/onci.28273 PMID: 25050201

28. Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA,
Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, Wolff AC, Wood WC, Davidson NE, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014; 32:2959–66. https://doi.org/10.1200/JCO.2013.55.0491 PMID:25071121

29. Dong M, Shi Y, Yang J, Zhou Q, Lian Y, Wang D, Ma T, Zhang Y, Mi Y, Gu X, Fan R. Prognostic and clinicopathological significance of systemic immune-inflammation index in colorectal cancer: a meta-analysis. Ther Adv Med Oncol. 2020; 12:1758835920937425. https://doi.org/10.1177/1758835920937425 PMID:32699557

30. Huang Y, Gao Y, Wu Y, Lin H. Prognostic value of systemic immune-inflammation index in patients with urologic cancers: a meta-analysis. Cancer Cell Int. 2020; 20:499. https://doi.org/10.1186/s12935-020-01590-4 PMID:33061851

31. Ji Y, Wang H. Prognostic prediction of systemic immune-inflammation index for patients with gynecological and breast cancers: a meta-analysis. World J Surg Oncol. 2020; 18:197. https://doi.org/10.1186/s12957-020-01974-w PMID:32767977

32. Wang B, Huang Y, Lin T. Prognostic impact of elevated pre-treatment systemic immune-inflammation index (SII) in hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore). 2020; 99:e18571. https://doi.org/10.1097/MD.0000000000018571 PMID:31895801

33. Zhang Y, Sun Y, Zhang Q. Prognostic value of the systemic immune-inflammation index in patients with breast cancer: a meta-analysis. Cancer Cell Int. 2020; 20:224. https://doi.org/10.1186/s12935-020-01308-6 PMID:32528232

34. Moher D, Liberati A, Tetzlaff J, Altman DG, and PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6:e1000097. https://doi.org/10.1371/journal.pmed.1000097 PMID:19621072

35. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25:603–05. https://doi.org/10.1007/s10654-010-9491-z PMID:20652370
SUPPLEMENTARY MATERIALS

Supplementary Table

Please browse Full Text version to see the data of Supplementary Table 1.

Supplementary Table 1. Baseline characteristics of included studies in this meta-analysis.